Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Malignant Breast Neoplasm, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm, Malignant Solid Neoplasm
Interventions: Computed Tomography, Fluorine F 18-fluoroazomycin Arabinoside, Positron Emission Tomography; Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiovascular Kidney Metabolic Syndrome, Type 2 Diabetes
Interventions: Exercise is Medicine (EIM), Culinary Education, Food is Medicine, Nutrition Counseling, Participant Website; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Columbus, Ohio • Upper Arlington, Ohio

Conditions: Chronic Kidney Disease, Secondary Hyperparathyroidism
Interventions: Etelcalcetide; Drug
Lead sponsor: Amgen; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 3
States / cities: Los Angeles, California • Louisville, Kentucky • Kansas City, Missouri

Conditions: Diabetes, Heart Disease, Hypertension
Interventions: CARIÑO Project, Enhanced Usual Care; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 35 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions: PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 16 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 31
States / cities: Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more

Conditions: Diabetes Mellitus, Type 2
Interventions: JNJ-64565111, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 2
States / cities: Chula Vista, California • Miami, Florida

Conditions: Thyroid Nodule
Interventions: Contrast-enhanced ultrasound, Shear Wave Elastography, Sequoia System; Other · Device
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Type 2 Diabetes
Interventions: Treatment Algorithms; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Pancreatic Cancer
Interventions: Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab, IMC-CS4; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo identical to BI10773 high dose, BI 10773, BI 10773 open label, Placebo identical to BI10773 low dose, Placebo identical to Sitagliptin 100mg, BI10773, Sitagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 986 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 27
States / cities: Mesa, Arizona • Phoenix, Arizona • Hot Springs, Arkansas + 23 more

Conditions: Congenital Adrenal Hyperplasia (CAH), Familial Male-Limited Precocious Puberty (FMPP)
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 1 Day to 99 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Non Insulin Dependent Diabetes, Pregnancy
Interventions: Metformin, Insulin; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetic Neuropathy, Chemotherapy Induced Neuropathy, HIV Neuropathy, Trauma Induced Neuropathy
Interventions: Neuron012703 (Medical Food); Drug
Lead sponsor: Targeted Medical Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Carcinoma, Colon Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Kidney Carcinoma, Lung Carcinoma, Ovarian Carcinoma, Pancreatic Carcinoma, Solid Neoplasm, Uterine Corpus Cancer
Interventions: Computed Tomography, Gallium Ga 68 FAPi-46, Gallium Ga 68-labeled PSMA-11, Positron Emission Tomography, 18F-FDG; Procedure · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome
Interventions: Rosuvastatin Calcium, Placebo Oral Tablet, Coenzyme Q10, Calcium Carbonate, Vitamin D; Drug · Dietary Supplement
Lead sponsor: Dr. B. Catharine. Craven; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pancreatic Cancer
Interventions: Ablation of Celiac Ganglion; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Diet, Cooking
Interventions: Cooking Intervention; Behavioral
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetic Retinopathy
Interventions: BI 764524, Sham comparator to BI 764524, Aflibercept (Eylea®) - US only; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 40
States / cities: Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 33 more

Conditions: Ovarian Cancer
Interventions: filgrastim, melphalan, thiotepa, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years · Female only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes, Hypertension
Interventions: Financial Incentive Group I, Financial Incentive Group II; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 40
States / cities: Birmingham, Alabama • Anchorage, Alaska • Duarte, California + 36 more

Conditions: Type 1 Diabetes Mellitus, Diabetic Ketoacidosis
Interventions: Not listed
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 3 Years to 18 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Chronic Kidney Disease
Interventions: Calcium acetate, Lanthanum Carbonate, Sevelamer Carbonate, Placebo; Drug
Lead sponsor: Denver Nephrologists, P.C.; Other
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Nonresectable Adrenocortical Carcinoma
Interventions: Iressa (ZD1839); Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 4
States / cities: Louisville, Kentucky • Boston, Massachusetts • Lebanon, New Hampshire + 1 more

Search by objective public record fields.

18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients

Food and Fitness With Medicine (FFWM)

A Single-dose Study in Paediatric Patients Aged 2 to Less Than 18 Years With Secondary Hyperparathyroidism (sHPT) Receiving Haemodialysis

Miami Healthy Heart Initiative a Behavioral Study on Cardiovascular Risk Factors

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

Utility of Contrast-Enhanced Sonography and Shear Wave Elastography

REMEDIES4D: REdesigning MEDication Intensification Effectiveness Study for Diabetes

Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas

Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

Natural History Study of Patients With Excess Androgen

Effectiveness of Metformin Compared to Insulin in Pregnant Women With Mild Preexisting or Early Gestational Diabetes

A Clinical Outcomes Study to Measure Reduction in Pain and Numbness During Administration of an Amino Acid Formulation in Subjects Diagnosed With Peripheral Neuropathy

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk

Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer

Dietary Behavior Intervention in African Americans at Risk for Cardiovascular Disease

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Melphalan and Thiotepa Followed by Peripheral Stem Cell Transplantation in Treating Patients With Epithelial Ovarian Cancer in Complete Remission

Way to Health, Healthy Measures

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

Diabetic Kidney Alarm (DKA) Study

A Double Blind Randomized Placebo Trial of Maintenance of Normal Serum Phosphorus in CKD

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)